Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atovaquone/Proguanil · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Azithromycin/Chloroquine | DRUG | - |
| Atovaquone/Proguanil | DRUG | - |
Inclusion Criteria: * Written informed consent of the subject or a legally authorized representative * Females and males \>= 18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual par...
Atovaquone/Proguanil is used for the treatment of uncomplicated Plasmodium falciparum malaria. It is a small molecule being developed by Pfizer, Inc. for the infectious disease indication of malaria, specifically falciparum malaria.
Atovaquone/Proguanil is a combination of two antimalarial drugs. Atovaquone inhibits the mitochondrial electron transport chain in the malaria parasite, while proguanil, through its metabolite cycloguanil, inhibits dihydrofolate reductase. Together they work synergistically to kill the Plasmodium falciparum parasite.
Atovaquone/Proguanil is developed by Pfizer, Inc., which is listed on the stock exchange under the ticker PFE. The company is conducting clinical development of this drug for the treatment of falciparum malaria.
Atovaquone/Proguanil is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied for the treatment of uncomplicated Plasmodium falciparum malaria.
Atovaquone/Proguanil has one completed Phase 2 clinical trial with the identifier NCT00084227. This trial compared azithromycin plus chloroquine versus atovaquone-proguanil for the treatment of uncomplicated Plasmodium falciparum malaria in South America, enrolling 244 participants.
Atovaquone/Proguanil is the generic name for the combination drug also known by the brand name Malarone. The drug combines atovaquone and proguanil hydrochloride and is used for the prevention and treatment of malaria.